This Is MS Multiple Sclerosis Community: Knowledge & Support

Sanofi SA risks falling behind in the battle for share of the fast-growing multi-billion euro multiple sclerosis (MS) market, as rivals push ahead with revolutionary treatments while doubts remain over the French drugmaker's own drug candidates.

Sanofi, which has relied on blood thinners and cancer therapies to drive sales but faces increased competition from generic drug versions, is preparing to submit two MS treatments for approval this year.

But it faces an uphill battle to catch Novartis AG's Gilenya and Biogen Idec Inc's BG-12, set to dominate a market that JPMorgan analysts see growing to $14 billion (8 billion pound) in 2015 from $9.6 billion last year.

"Sanofi will remain a small player compared with Biogen or Novartis, but it will still remain on the radar screen," said Beatrice Muzard, an analyst at brokerage Natixis.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis